Trials / Terminated
TerminatedNCT04775797
Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AB-836, an HBV Capsid Inhibitor, in Healthy Subjects and Subjects With Chronic HBV Infection
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 110 (actual)
- Sponsor
- Arbutus Biopharma Corporation · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This three-part, Phase 1 protocol will be the first clinical study of AB-836. Parts 1 and 2a/b will be a Phase 1a SAD/MAD of AB-836 in healthy adult subjects. Part 3 will be a Phase 1b dose-ranging assessment of AB-836 in non-cirrhotic Chronic Hepatitis B (CHB) subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AB-836 | Capsules or Tablets |
| DRUG | Placebo | Capsules of Tablets |
| DRUG | AB-836 | Tablets |
| DRUG | Placebo | Tablets |
| DRUG | Nucleos(t)ide Analogue | Tablets |
Timeline
- Start date
- 2021-06-25
- Primary completion
- 2022-11-17
- Completion
- 2022-11-17
- First posted
- 2021-03-01
- Last updated
- 2022-11-21
Locations
15 sites across 8 countries: Australia, Canada, Hong Kong, Moldova, New Zealand, South Korea, Thailand, Ukraine
Source: ClinicalTrials.gov record NCT04775797. Inclusion in this directory is not an endorsement.